AB-3PRGD2

AB-3PRGD2 is a radiolabeled agent that targets integrin αvβ3. It enhances tumor uptake and prolongs retention time in tumors, significantly improving the inhibition of tumor growth. AB-3PRGD2 also remodels the tumor immune microenvironment by upregulating PD-L1 expression and increasing tumor-infiltrating CD8+ T cells.

S(C[C@H](NC(CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1)=O)C(N[C@H](CCCCNC(CCCC2=CC=C(I)C=C2)=O)C(O)=O)=O)C3C(=O)N(CCCCCC(NCCOCCOCCOCCOCCC(N[C@@H](CCC(NCCOCCOCCOCCOCCC(NCCCC[C@@H]4NC(=O)[C@@H](CC5=CC=CC=C5)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC4=O)=O)=O)C(NCCOCCOCCOCCOCCC(NCCCC[C@@H]6NC(=O)[C@@H](CC7=CC=CC=C7)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC6=O)=O)=O)=O)=O)C(=O)C3